Monitor for the upcoming data and regulatory plan update for ARCT-810 later this quarter, which could serve as a catalyst. The current filing is a routine scientific presentation with no immediate trading implications.
Price Chart
Executive Summary
Arcturus Therapeutics presented a poster on its ARCT-810 mRNA therapy for Ornithine Transcarbamylase (OTC) Deficiency at the 2026 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism. The filing is a routine Regulation FD disclosure of a scientific presentation with no new financial data or guidance. The company noted additional data and the regulatory plan for this program are expected later this quarter, providing a modest pipeline update but no material change in fundamentals.
Key Facts
- Arcturus presented a poster titled 'Impact of ARCT-810 mRNA Therapy on Dietary Intake and Biochemical Data in Adolescents and Adults with Ornithine Transcarbamylase Deficiency' at the 2026 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism in Helsinki, Finland.
- Additional data and the regulatory plan for the ARCT-810 program are expected to be communicated later this quarter.
- No financial results, guidance, or material agreements were disclosed in this filing.
Financial Impact
No financial impact disclosed in this filing.
Risk Factors
- Clinical trial data may not meet expectations.
- Regulatory pathway for ARCT-810 remains uncertain until the plan is detailed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193805-26-001130 |
| Document: 0001193805-26-001130-index.html | 0001193805-26-001130 |
| Document: 0001193805-26-001130.txt | 0001193805-26-001130 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | SC 13G/A | $12.77 | awaiting T+20 | — | $9.93 (−22.25%) |
Sep 28, 2026 28d ago | Court Ruling | $13.70 | awaiting T+20 | — | $9.93 (−27.55%) |
Aug 25, 2026 8w ago | 8-K | $15.44 $14.69 | ▼ −4.86% | ▼ −6.10% | $9.93 (−35.72%) |
Aug 15, 2026 10w ago | Institutional Cluster | $8.14 $15.84 | ▲ +94.59% | ▲ +96.57% | $9.93 (+21.93%) |
Jul 2, 2026 16w ago | 8-K | $7.28 $5.92 | ▼ −18.68% | ▼ −18.27% | $9.93 (+36.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers